Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

24. September 2025 08:30 ET | Quelle: Er-Kim Pharmaceuticals

Er-Kim Enters Commercialization Agreement with Sentynl Therapeutics for Nulibry® (fosdenopterin) and Zokinvy® (lonafarnib), Targeting Ultra-Rare Diseases

Distribution agreement expands access of Nulibry and Zokinvy to 33 countries within CEE, the Mediterranean, and Eurasia
26. August 2025 05:00 ET | Quelle: Er-Kim Pharmaceuticals

Er-Kim Announces Exclusive Agreement with CNX Therapeutics to Distribute Oncology Products Across CEE and Turkey

Er-Kim signs distribution agreement with CNX Therapeutics to distribute its portfolio of oncology medications across CEE and Turkey.
30. Juni 2025 08:00 ET | Quelle: Er-Kim Pharmaceuticals

Er-Kim Announces Exclusive Agreement with Immunocore to Distribute KIMMTRAK in Turkey, and the MENA, Caucasus and CIS Regions

Er-Kim has partnered with Immunocore to bring KIMMTRAK (tebentafusp) to patients in Turkey, MENA, Caucasus, and CIS regions
14. Januar 2025 08:00 ET | Quelle: Er-Kim

Er-Kim Announces Exclusive Distribution Agreement with the MEDICE Health Family For Vafseo® in Central & Eastern Europe

Er-Kim's partnership will support access of an alternative treatment to improve the lives of people impacted by anemia caused by chronic kidney disease